Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 8, Issue 16
August 27 2024
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Ending endless follow-up for low-risk CLL?
Philip A. Thompson
View Articletitled, Ending endless follow-up for low-risk CLL?
Doubling down on PK activation for sickle cell disease
Clinical Trials & Observations
Samuel R. Wilson,Lydia H. Pecker
View Articletitled, Doubling down on PK activation for sickle cell disease
Metformin for MPN: teaching an old drug new tricks
Michelle H. Lee,Gabriela S. Hobbs
View Articletitled, Metformin for MPN: teaching an old drug new tricks

REVIEW ARTICLES

CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
Clinical Trials & Observations
Fabiana Perna,Samir Parekh,Caroline Diorio,Melody Smith,Marion Subklewe,Rakesh Mehta,Frederick L. Locke,Nirali N. Shah
View Articletitled, CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations
Beyond BCMA: newer immune targets in myeloma
Melinda S. Y. Tan,Yunxin Chen,Eric L. Smith
View Articletitled, Beyond BCMA: newer immune targets in myeloma

CLINICAL TRIALS AND OBSERVATIONS

High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention
Clinical Trials & Observations
Noa G. Holtzman,Lauren M. Curtis,Rachel B. Salit,Brian C. Shaffer,Filip Pirsl,Alen Ostojic,Seth M. Steinberg,Eduard Schulz,Jennifer S. Wilder,Thomas E. Hughes,Jeremy Rose,Sarfraz Memon,Robert Korngold,Juan C. Gea-Banacloche,Daniel H. Fowler,Frances T. Hakim,Ronald E. Gress,Michael R. Bishop,Steven Z. Pavletic
View Articletitled, High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention
Supplemental data
Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial
Clinical Trials & Observations
Eugene Oteng-Ntim,Laura L. Oakley,Vicky Robinson,Sarah Brien,Jeannine Joseph,Joseph Sharif,Laura McCabe,Hilary Thompson,Moji Awogbade,Jemma Johns,Denise M. Brunetta,Paul T. Seed
View Articletitled, Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial
Supplemental data
It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia
Clinical Trials & Observations
Christian Brieghel,Caspar da Cunha-Bang,Jindrich Mourek,Lars Kjeldsen,Carsten U. Niemann
View Articletitled, It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia
Supplemental data
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease
Clinical Trials & Observations
Santosh L. Saraf,Robert Hagar,Modupe Idowu,Ifeyinwa Osunkwo,Kimberly Cruz,Frans A. Kuypers,R. Clark Brown,James Geib,Maria Ribadeneira,Patricia Schroeder,Eric Wu,Sanjeev Forsyth,Patrick F. Kelly,Theodosia A. Kalfa,Marilyn J. Telen
View Articletitled, Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease
Supplemental data
Metformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study
Clinical Trials & Observations
Daniel Tuyet Kristensen,Andreas Kiesbye Øvlisen,Lasse Hjort Kyneb Jakobsen,Marianne Tang Severinsen,Louise Hur Hannig,Jørn Starklint,Morten Hagemann Hilsøe,Anders Pommer Vallentin,Mette Brabrand,Hans Carl Hasselbalch,Tarec Christoffer El-Galaly,Anne Stidsholt Roug
View Articletitled, Metformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study
Supplemental data

HEALTH SERVICES AND OUTCOMES

Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention
Fateeha Furqan,Vineel Bhatlapenumarthi,Binod Dhakal,Timothy S. Fenske,Faiqa Farrukh,Walter Longo,Othman Akhtar,Anita D’Souza,Marcelo Pasquini,Guru Subramanian Guru Murthy,Lyndsey Runaas,Sameem Abedin,Meera Mohan,Nirav N. Shah,Mehdi Hamadani
View Articletitled, Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention
Supplemental data
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL
Arushi Khurana,Raphael Mwangi,Loretta J. Nastoupil,Patrick M. Reagan,Umar Farooq,Jason T. Romancik,Timothy J. McDonnell,Shaun M. Riska,lzidore S. Lossos,Brad S. Kahl,Peter Martin,Thomas E. Witzig,James R. Cerhan,Christopher R. Flowers,Grzegorz S. Nowakowski,Matthew J. Maurer
View Articletitled, Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia
Anne-Charlotte Le Floch,Florence Orlanducci,Marie-Christine Béné,Amira Ben Amara,Marie-Sarah Rouviere,Nassim Salem,Aude Le Roy,Charlotte Cordier,Clémence Demerlé,Samuel Granjeaud,Jean-François Hamel,Norbert Ifrah,Pascale Cornillet-Lefebvre,Jacques Delaunay,Christian Récher,Eric Delabesse,Arnaud Pigneux,Norbert Vey,Anne-Sophie Chretien,Daniel Olive
View Articletitled, Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia
Supplemental data

LYMPHOID NEOPLASIA

IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence
Jacob D. Soumerai,Zaid Yousif,Thais Gift,Raj Desai,Lynn Huynh,Mingchen Ye,Azeem Banatwala,Louise Clear,Megan Pinaire,Gregory Belsky,Yichuan Grace Hsieh,Christopher Herrick,Eli P. Darnell,Mei Sheng Duh,Marie Sanchirico,Shawn N. Murphy
View Articletitled, IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence
Supplemental data
Tumor microenvironment of Burkitt lymphoma: different immune signatures with different clinical behavior
Maria Chiara Siciliano,Giorgio Bertolazzi,Gaia Morello,Salvatore Tornambè,Marcello Del Corvo,Massimo Granai,Maria Rosaria Sapienza,Ciara I. Leahy,Eanna Fennell,Beatrice Belmonte,Felice Arcuri,Margherita Vannucchi,Virginia Mancini,Raffaella Guazzo,Roberto Boccacci,Noel Onyango,Joshua Nyagol,Raffaella Santi,Gioia Di Stefano,Domenico Ferrara,Cristiana Bellan,Teresa Marafioti,German Ott,Reiner Siebert,Leticia Quintanilla-Fend,Falko Fend,Paul Murray,Claudio Tripodo,Stefano Pileri,Stefano Lazzi,Lorenzo Leoncini
View Articletitled, Tumor microenvironment of Burkitt lymphoma: different immune signatures with different clinical behavior
Supplemental data
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression
Joana de Matos Rodrigues,Lavanya Lokhande,Lina M. Olsson,May Hassan,Angelica Johansson,Anna Janská,Darshan Kumar,Lina Schmidt,Anna Nikkarinen,Peter Hollander,Ingrid Glimelius,Anna Porwit,Anna Sandstrom Gerdtsson,Mats Jerkeman,Sara Ek
View Articletitled, CD163<sup>+</sup> macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression
Supplemental data
Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population–based analysis
Clinical Trials & Observations
Jorge A. Florindez,Dai Chihara,Isildinha M. Reis,Izidore S. Lossos,Juan Pablo Alderuccio
View Articletitled, Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population–based analysis
Supplemental data

PLATELETS AND THROMBOPOIESIS

An αIIbβ3 monoclonal antibody traps a semiextended conformation and allosterically inhibits large ligand binding
Lu Wang,Jialing Wang,Jihong Li,Thomas Walz,Barry S. Coller
View Articletitled, An αIIbβ3 monoclonal antibody traps a semiextended conformation and allosterically inhibits large ligand binding
Supplemental data

THROMBOSIS AND HEMOSTASIS

Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis
Omid Seidizadeh,Andrea Cairo,Ilaria Mancini,James N. George,Flora Peyvandi
View Articletitled, Global prevalence of hereditary thrombotic thrombocytopenic purpura determined by genetic analysis
Supplemental data

TRANSFUSION MEDICINE

Maternal red blood cell alloimmunization prevalence in the United States
Ronan P. Sugrue,Kenneth J. Moise,Jerome J. Federspiel,Elizabeth Abels,Judy Z. Louie,Zhen Chen,Lance Bare,Damian P. Alagia,Harvey W. Kaufman
View Articletitled, Maternal red blood cell alloimmunization prevalence in the United States
Supplemental data

TRANSPLANTATION

Associations between acute and chronic graft-versus-host disease
Masaharu Tamaki,Yu Akahoshi,Yoshihiro Inamoto,Kaoru Morita,Naoyuki Uchida,Noriko Doki,Masatsugu Tanaka,Tetsuya Nishida,Hiroyuki Ohigashi,Hirohisa Nakamae,Makoto Onizuka,Yuta Katayama,Ken-ichi Matsuoka,Masashi Sawa,Fumihiko Ishimaru,Yoshinobu Kanda,Takahiro Fukuda,Yoshiko Atsuta,Seitaro Terakura,Junya Kanda
View Articletitled, Associations between acute and chronic graft-versus-host disease
Supplemental data
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Tania Jain,Noel Estrada-Merly,M. Queralt Salas,Soyoung Kim,Jakob DeVos,Min Chen,Xi Fang,Rajat Kumar,Marcio Andrade-Campos,Hany Elmariah,Vaibhav Agrawal,Mahmoud Aljurf,Ulrike Bacher,Talha Badar,Sherif M. Badawy,Karen Ballen,Amer Beitinjaneh,Vijaya Raj Bhatt,Christopher Bredeson,Zachariah DeFilipp,Bhagirathbhai Dholaria,Nosha Farhadfar,Shatha Farhan,Arpita P. Gandhi,Siddhartha Ganguly,Usama Gergis,Michael R. Grunwald,Nada Hamad,Betty K. Hamilton,Yoshihiro Inamoto,Madiha Iqbal,Omer Jamy,Mark Juckett,Mohamed A. Kharfan-Dabaja,Maxwell M. Krem,Deepesh P. Lad,Jane Liesveld,Monzr M. Al Malki,Adriana K. Malone,Hemant S. Murthy,Guillermo Ortí,Sagar S. Patel,Attaphol Pawarode,Miguel-Angel Perales,Marjolein van der Poel,Olle Ringden,David A. Rizzieri,Alicia Rovó,Bipin N. Savani,Mary Lynn Savoie,Sachiko Seo,Melhem Solh,Celalettin Ustun,Leo F. Verdonck,John R. Wingard,Baldeep Wirk,Nelli Bejanyan,Richard J. Jones,Taiga Nishihori,Betul Oran,Ryotaro Nakamura,Bart Scott,Wael Saber,Vikas Gupta
View Articletitled, Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study
Supplemental data

RESEARCH LETTERS

Platelet proteomic profiling reveals potential mediators of immunothrombosis and proteostasis in myeloproliferative neoplasms
Sarah Kelliher,Sara Gamba,Luisa Weiss,Zhu Shen,Marina Marchetti,Francesca Schieppati,Caitriona Scaife,Stephen Madden,Kathleen Bennett,Anne Fortune,Su Maung,Michael Fay,Fionnuala Ní Áinle,Patricia Maguire,Anna Falanga,Barry Kevane,Anandi Krishnan
View Articletitled, Platelet proteomic profiling reveals potential mediators of immunothrombosis and proteostasis in myeloproliferative neoplasms
Supplemental data
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial
Clinical Trials & Observations
Adriano Venditti,Alfonso Piciocchi,Anna Candoni,Valentina Arena,Raffaele Palmieri,Carla Filì,Angelo Michele Carella,Valeria Calafiore,Roberto Cairoli,Paolo de Fabritiis,Gabriella Storti,Prassede Salutari,Francesco Lanza,Giovanni Martinelli,Antonio Curti,Mario Luppi,Claudia Ingrosso,Maria Paola Martelli,Antonio Cuneo,Francesco Albano,Antonino Mulè,Agostino Tafuri,Laura Cudillo,Alessia Tieghi,Nicola Stefano Fracchiolla,Debora Capelli,Silvia Maria Trisolini,Caterina Alati,Edoardo La Sala,Luca Maurillo,Maria Ilaria Del Principe,Maria Antonietta Irno Consalvo,Maria Domenica Divona,Tiziana Ottone,Raffaella Cerretti,Giuseppe Sconocchia,Maria Teresa Voso,Paola Fazi,Marco Vignetti,Francesco Buccisano
View Articletitled, Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial
Supplemental data

COMMENTARY

Interleukin-1β, JAK2V617F mutation and inflammation in MPNs
Sylvie Hermouet,Hans C. Hasselbalch
View Articletitled, Interleukin-1β, <em>JAK2</em>V617F mutation and inflammation in MPNs

ERRATUM

Dalby A, Mezzano D, Rivera J, et al. Introduction of an ancient founder glycoprotein VI mutation into the Chilean population. Blood Adv. 2022;6(22):5866-5869.
View Articletitled, Dalby A, Mezzano D, Rivera J, et al. Introduction of an ancient founder glycoprotein VI mutation into the Chilean population. <em>Blood Adv</em>. 2022;6(22):5866-5869.
  • Cover Image

    Cover Image

    issue cover

    Multiplex immunofluorescence staining of the tissue from a patient with mantle cell lymphoma showing the presence of both CD163+ and CD11c+ immune cells in the microenvironment. See the article by de Matos Rodrigues et al.

All Issues

Advertisement intended for health care professionals

A contemporary downtrend in chronic GVHD?
Imus PH, Pasca S, Tsai H-L, et al. Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies. Blood Adv. 2024;8(14):3849-3858.
Glisovic-Aplenc T, Diorio C, Chukinas JA, et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv. 2023;7(16):4418-4430.
Sewastianik T, Jiang M, Sukhdeo K, et al. Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Adv. 2017;1(25):2361-2374.
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals